Sihuan Pharmaceutical Holdings Group Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Beijing China (2001)
Status: No NME R&D (2001)

Organization Overview

First Clinical Trial
2014
NCT02299804
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Sihuan Pharmaceutical Holdings Group Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 1)

Communicable Diseases (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Dizziness (Phase 2)

Duodenal Ulcer (Phase 3)

Infections (Phase 3)

Lung Neoplasms (Phase 1)

Motion Sickness (Phase 2)

Neoplasm Metastasis (Phase 2)

Pyelonephritis (Phase 3)

Ulcer (Phase 3)

Urinary Tract Infections (Phase 3)

Vertigo (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 23
  • # of Trial APIs: 18